Keros Therapeutics: Strategic Alternatives Could Bring About Value Creation

2025-04-11 14:13:24 ET

Summary

• Keros Therapeutics, Inc. halted its phase 2 TROPOS trial of cibotercept for treatment of patients with PAH due to safety concerns, but expects topline data in Q2, 2025 from it.
• Promising phase 1 data for KER-065 in DMD and a strategic review could offer potential value despite risks that remain.
• In the 7 major markets, the global Duchenne Muscular Dystrophy market is expected to reach $5.2 billion by 2033.
• KROS is financially stable with $559.9 million in cash and a $200 million deal with Takeda, funding operations into 2029.

Keros Therapeutics, Inc. ( KROS ) suffered a major setback back in December 2024 when it announced that it had to halt its TROPOS phase 2 trial. This trial was evaluating the use of its drug cibotercept [KER-012] in combination with background therapy to treat patients with pulmonary arterial hypertension [PAH]. The reason for the halting of this mid-stage study was because of a safety review that was undertaken, whereby there were observations of pericardial effusion adverse events [AEs] in it....

Read the full article on Seeking Alpha

For further details see: